|
21 |
Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β‐Lactam Antibiotics
Enthalten in Advanced science 05.11.2024. 12 S.
|
|
|
|
22 |
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
Enthalten in BioDrugs 16.10.2024: 1-12
|
|
|
|
23 |
Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)
Enthalten in Aktuelle Rheumatologie 01.10.2024
|
|
|
|
24 |
Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials
Enthalten in Clinical and translational oncology 18.9.2024: 1-13
|
|
|
|
25 |
Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan
Enthalten in Inflammatory intestinal diseases Bd. 9, 2024, Nr. 1: 29-39. 11 S.
|
|
|
26 |
Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
Kirsten, Natalia. - Würzburg : Universität Würzburg, 2023
|
|
|
|
27 |
In Defense of Disinformation
Enthalten in Journal of homeland security and emergency management Bd. 21, 2023, Nr. 3: 441-466. 26 S.
|
|
|
|
28 |
Evaluating the Impact of Data Exclusivity on the Price of Pharmaceutical Imports
Enthalten in Journal of globalization and development Bd. 14, 2023, Nr. 1: 1-20. 20 S.
|
|
|
|
29 |
Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus
Enthalten in Journal of endocrinological investigation 26.12.2023: 1-12
|
|
|
|
30 |
Effektivität und Sicherheit nach einem Switch vom Originator Infliximab auf das Biosimilar SB2 bei CED-Patienten: 24-Monatsdaten einer prospektiven Kohortenstudie
Cohnen, Sarah. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2022
|
|
Administration
